Bristol Myers, 2seventy roll out full Abecma data in earlier-stage cancer
Bristol Myers Squibb and 2seventy bio teased a top-line win for their BCMA-targeting CAR-T Abecma in earlier stages of multiple myeloma back in August. Now they’re offering a look at the full data.
The biotech and Big Pharma pair put out word Friday that relapsed or refractory patients on Abecma in the KarMMa-3 Phase III pivotal trial saw a median 13.3 months of progression-free survival (PFS), meeting the trial’s primary endpoint. That’s more than the amount of time experienced by patients on one of five “standard regimens,” who saw a median 4.4 months of PFS (p<0.0001). The median follow-up time was 18.6 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.